ImmunityBio Inc Stock (ISIN: US45258J1025) Surges on NCCN Guideline Update and Buy Rating Reiteration

ImmunityBio Inc stock (ISIN: US45258J1025) jumps over 5% in pre-market trading after the NCCN expands ANKTIVA recommendations in bladder cancer guidelines, alongside a fresh 'Buy' rating from D. Boral Capital with a $23 target, signaling strong upside potential for investors eyeing biotech growth.

ImmunityBio Inc stock (ISIN: US45258J1025), a clinical-stage biotechnology firm focused on immunotherapy platforms, saw shares climb more than 5% in pre-market trading on March 17, 2026. The surge follows a significant update from the National Comprehensive Cancer Network (NCCN) expanding recommendations for its lead asset ANKTIVA in bladder cancer treatment, coupled with D. Boral Capital reiterating a 'Buy' rating and $23 price target.

As of: 17.03.2026

By Dr. Elena Voss, Senior Biotech Equity Analyst - 'Tracking immunotherapy breakthroughs shaping global oncology markets.'

Current Market Momentum for ImmunityBio Shares

ImmunityBio's NASDAQ-listed ordinary shares (IBRX) opened the day with notable pre-market gains, reflecting investor enthusiasm for fresh clinical endorsements. The stock's 50-day moving average stands at $6.74, with a 200-day average of $3.88, underscoring a bullish intermediate trend amid a market cap approaching $9.04 billion. While exact intraday pricing fluctuates, the implied 161.51% upside from D. Boral Capital's target highlights substantial growth expectations.

For European and DACH investors, ImmunityBio's U.S.-centric listing means access via Xetra or other platforms, where liquidity remains solid for high-conviction biotechs. The company's beta of -0.04 suggests low market correlation, appealing in volatile European equity environments.

NCCN Guideline Expansion: A Key Catalyst for ANKTIVA

The NCCN's 2026 bladder cancer guidelines now include ANKTIVA (formerly N-803), an IL-15 superagonist, for a broader patient population, even as full FDA approval for the expanded indication awaits. This update broadens potential use in non-muscle invasive bladder cancer (NMIBC), particularly BCG-unresponsive cases, driving the pre-market jump. ANKTIVA stimulates natural killer (NK) and T-cell activity, positioning it as a next-generation immunotherapy.

Market reaction underscores why this matters now: guideline inclusions often precede reimbursement and adoption surges. For ImmunityBio, this builds on 2025's 700% net product revenue growth to $113 million, fueled by repeat prescriptions and BCG supply shortages. Investors should note the therapy's still-limited FDA nod, tempering near-term revenue certainty.

Analyst Sentiment: Moderate Buy with Ambitious Targets

D. Boral Capital's reiterated 'Buy' rating on March 17 carries a $23 target, contrasting a consensus of $14.40 from one Strong Buy, five Buys, and one Sell. Recent actions include BTIG's March 12 initiation at 'Buy' ($13 target), Piper Sandler's March 4 overweight upgrade to $12, and HC Wainwright's February boost to $15. This cluster of upgrades signals rising confidence in ImmunityBio's pipeline.

From a DACH perspective, such U.S. analyst coverage influences European fund allocations, particularly as biotech valuations recover. However, the lone Sell rating warrants caution, likely tied to cash burn projections of $30-35 million for FY2026.

Financial Snapshot: Revenue Growth Amid Losses

ImmunityBio's Q4 2025 EPS beat estimates at -$0.06 versus -$0.08 expected, with $38.29 million in revenue. Full-year 2025 product sales soared 700% to $113 million, driven by ANKTIVA uptake. Forecasts peg FY2026 EPS at -0.92, reflecting R&D investments in the Cancer BioShield platform, encompassing adenovirus vaccines, NK-cell therapies, and immunomodulators.

Trading at a forward P/S of 33.86x versus the industry 2.00x, the stock commands a premium, justified by growth but vulnerable to misses. Zacks ranks it #3 (Hold), with mixed EPS estimate revisions over 60 days. Cash burn control remains pivotal for sustaining operations without dilution.

Business Model: Immunotherapy Platform Differentiation

ImmunityBio develops next-gen immunotherapies activating innate and adaptive immunity against cancer and infections. Core is the Cancer BioShield platform, anchored by ANKTIVA, with U.S. and European operations generating majority revenue stateside. Unlike monoclonal antibodies, its multi-modal approach - IL-15 agonists plus vectors - aims for durable responses, addressing resistance in solid tumors.

For European investors, ANKTIVA's 2026 EU approval for BCG-unresponsive NMIBC opens ex-U.S. markets, potentially mirroring U.S. BCG shortage dynamics. Saudi approvals further diversify geography, mitigating U.S.-only reliance.

Global Expansion and Revenue Drivers

ANKTIVA's international nods in the EU and Saudi Arabia since early 2026 position ImmunityBio for ex-U.S. growth, with repeat prescriptions and BCG constraints as tailwinds. U.S. NMIBC market demand persists, but guideline expansions could accelerate adoption pre-full approval.

DACH investors benefit indirectly via Europe's oncology focus; Swiss and German funds often overweight immuno-oncology. Trade-offs include regulatory hurdles abroad versus U.S. reimbursement speed.

Insider Activity and Ownership Dynamics

Insiders sold 501,967 shares worth $4.47 million last quarter, including Director Barry J. Simon's 75,000 shares at $12.01. Despite outflows, insiders retain 69.48% ownership, aligning interests with shareholders. Such sales post-rally are common in biotechs, but volume merits monitoring amid cash needs.

European investors scrutinize governance; high insider stakes provide comfort, though dilution risks loom if trials extend.

Valuation, Risks, and Competitive Landscape

At a P/E of -23.99, valuation hinges on pipeline success versus 2026 cash burn. Competitors in NK/IL-15 space include Bristol Myers Squibb and NKGen, but ImmunityBio's BioShield integration offers differentiation. Risks encompass FDA delays, trial failures, and competition; upsides from label expansions and partnerships.

Sector context: biotech indices rally on rate cuts, benefiting IBRX's low beta. DACH angle - German precision medicine funds may allocate, viewing ANKTIVA as synergistic with CAR-T advances.

Outlook: Catalysts Ahead for Investors

Near-term catalysts include FDA feedback on expanded indications, Q1 earnings, and international launches. Consensus targets imply 75%+ upside, with D. Boral's outlier at 161%. For conservative DACH portfolios, position sizing balances biotech volatility against immunotherapy megatrend.

Longer-term, platform validation could drive multi-bagger returns, contingent on execution. European regulatory alignment enhances appeal for diversified investors.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.